Most Evidence-Based Biologic for Hidradenitis Suppurativa
Adalimumab (40 mg weekly) is the most evidence-based biologic for hidradenitis suppurativa, supported by FDA approval, the largest phase 3 trial data, and recent network meta-analysis demonstrating superior efficacy and safety compared to other biologics. 1, 2
Why Adalimumab Stands Above Other Biologics
Adalimumab is the only FDA-approved biologic specifically for moderate-to-severe HS, with the most robust clinical trial evidence 1. The PIONEER 1 and 2 trials established its efficacy using weekly dosing (160 mg at week 0,80 mg at week 2, then 40 mg weekly starting week 4), achieving HiSCR response rates of 42% versus 26% placebo (PIONEER 1, P=.003) and 59% versus 28% placebo (PIONEER 2) at 12 weeks 1.
Critical dosing insight: Every-other-week dosing failed to meet primary endpoints in four earlier trials, but weekly dosing proved significantly more effective (17.6% response vs 9.6% every-other-week vs 3.9% placebo in phase 2 trials) 1. This weekly regimen is essential for optimal outcomes.
A 2025 network meta-analysis of all phase 3 trials (2,731 patients across PIONEER, SUNSHINE/SUNRISE, and BE HEARD studies) ranked adalimumab weekly as most effective for achieving HiSCR50, with significant superiority over secukinumab every 2 weeks (OR=1.74,95% CI: 1.11-2.73) and every 4 weeks (OR=1.72,95% CI: 1.09-2.7), and numerical superiority over bimekizumab 2. Adalimumab also demonstrated the fewest adverse events with significant superiority over bimekizumab every 2 weeks (OR=0.52,95% CI: 0.32-0.86) 2.
Second-Line Options When Adalimumab Fails
If adalimumab fails or is contraindicated, secukinumab (IL-17A inhibitor, FDA-approved in 2024) represents the next best option 3, 4, 5. Bimekizumab (dual IL-17A/F inhibitor, approved 2024) shows promise but had higher adverse event rates in head-to-head comparisons 2, 6.
Important persistence note: Among initial non-responders to adalimumab at 12 weeks, nearly 40% achieved response by 36 weeks with continued treatment 1. Don't abandon therapy prematurely—give it at least 36 weeks before declaring treatment failure.
Common Pitfalls to Avoid
Underdosing: Using every-other-week adalimumab instead of weekly dosing will result in suboptimal outcomes. The evidence clearly supports weekly maintenance 1.
Premature discontinuation: Almost half of week-12 responders lost response at week 36, but this doesn't mean treatment failure—it reflects the chronic relapsing nature of HS requiring sustained therapy 1.
Ignoring concomitant therapy: In PIONEER 2,19% continued tetracycline-class antibiotics during biologic treatment 1. Consider maintaining oral antibiotics during biologic initiation for additive benefit.
Expecting complete clearance: HiSCR (≥50% reduction in inflammatory lesions with no increase in abscesses/draining fistulas) is the realistic endpoint, not complete remission. Set appropriate patient expectations.
When to Initiate Biologic Therapy
Start adalimumab for moderate-to-severe HS after inadequate response to conventional therapy, though emerging expert consensus suggests earlier initiation in patients with rapidly progressing disease, extensive involvement, frequent flares during antibiotic treatment, or significant comorbidities 7. The traditional requirement of 10-12 weeks of antibiotics before biologics may delay optimal intervention and miss therapeutic windows 7.
For acute flares while initiating biologics, bridge with prednisone 0.5-1 mg/kg daily tapers—this provides rapid substantial effect while waiting for biologic onset 1.